keyword
MENU ▼
Read by QxMD icon Read
search

Tardive dyskinesia

keyword
https://www.readbyqxmd.com/read/28212067/the-treatment-of-severe-childhood-aggression-study-12-weeks-of-extended-blinded-treatment-in-clinical-responders
#1
Robert L Findling, Lisa Townsend, Nicole V Brown, L Eugene Arnold, Kenneth D Gadow, David J Kolko, Nora K McNamara, Devin S Gary, Dana B Kaplin, Cristan A Farmer, Heidi Kipp, Craig Williams, Eric M Butter, Oscar G Bukstein, Robert Rice, Kristin Buchan-Page, Brooke S G Molina, Michael G Aman
OBJECTIVES: Previous "Treatment of Severe Childhood Aggression" (TOSCA) reports demonstrated that many children with severe physical aggression and attention-deficit/hyperactivity disorder (ADHD) responded well to two randomized treatments (parent training [PT]+stimulant+placebo = Basic vs. PT+stimulant+risperidone = Augmented) for 9 weeks. An important clinical question is whether these favorable outcomes are maintained over longer times. METHODS: Clinical responders to the 9-week trial (n = 103/168), defined as Clinical Global Impressions (CGI)-Improvement of much/very much improved plus substantial reduction in parent ratings of disruptiveness, were followed another 12 weeks (21 weeks total) while remaining on blinded treatment...
February 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28207919/tardive-dyskinesia-21st-century-may-bring-new-treatments-to-a-forgotten-disorder
#2
Gopalkumar Rakesh, Andrew Muzyk, Steven T Szabo, Sanjay Gupta, Chi-Un Pae, Prakash Masand
BACKGROUND: Tardive dyskinesia (TD) is a condition that was first described nearly 60 years ago. Despite the tremendous amount of research on pathophysiology and numerous follow-up studies to understand the course and prognosis of TD, effective treatment of the condition continued to elude us until recently. METHODS: We review and summarize clinical literature on TD, as well as provide an update on new treatments available. RESULTS: The emergence of tetrabenazine as a treatment modality decreased suffering and improved quality of life for patients...
February 1, 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28199071/effect-of-antipsychotic-type-and-dose-changes-on-tardive-dyskinesia-and-parkinsonism-severity-in-patients-with-a-serious-mental-illness-the-cura%C3%A3-ao-extrapyramidal-syndromes-study-xii
#3
Charlotte L Mentzel, P Roberto Bakker, Jim van Os, Marjan Drukker, Glenn E Matroos, Hans W Hoek, Marina A J Tijssen, Peter N van Harten
OBJECTIVE: To test the efficacy of current treatment recommendations for parkinsonism and tardive dyskinesia (TD) severity in patients with severe mental illness (SMI). METHODS: We present an 18-year prospective study including all 223 patients with SMI (as defined by the 1987 US National Institute of Mental Health, which were based on DSM-III-R diagnostic criteria) receiving care from the only psychiatric hospital of the former Netherlands Antilles. Eight clinical assessments (1992-2009) focused on movement disorders and medication use...
February 14, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28195931/should-antipsychotic-medications-for-schizophrenia-be-given-for-a-lifetime-a-naturalistic-long-term-follow-up-study
#4
Ira D Glick, John M Davis, Daisy Zamora, Jacob Ballon, Meena Nuthi
BACKGROUND: Schizophrenia remains a major health problem despite antipsychotic medications that, for most patients, can decrease acute symptoms, decrease relapses, and contribute to partial and sometimes strong positive response in patients with chronic symptoms. What has not been clear-because a double-blind, randomized, placebo-controlled trial is not feasible or ethical-is how many years after the initial episode, or onset of antipsychotic treatment, should medication be continued to achieve the best global outcome...
February 13, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28167465/co-treatment-with-imipramine-averted-haloperidol-instigated-tardive-dyskinesia-association-with-serotonin-in-brain-regions
#5
Noreen Samad, Farzana Yasmin, Darakhshan Jabeen Haleem
Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD). 0.2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks. Following 2 weeks co-injection 5 mg/kg dosage of IMI was diminished haloperidol-instigated VCMs and fully averted following five weeks. The potency of 8-OH-DPAT-instigated locomotor activity exhibited higher in saline+haloperidol treated rats while not observed in IMI+ haloperidol treated rats...
November 2016: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28146614/tardive-dyskinesia-prevalence-in-the-period-of-second-generation-antipsychotic-use-a-meta-analysis
#6
Maren Carbon, Cheng-Hsi Hsieh, John M Kane, Christoph U Correll
OBJECTIVE: Comparison of tardive dyskinesia (TD) prevalence during contemporaneous treatment with first-generation antipsychotics (FGAs) and/or second-generation antipsychotics (SGAs). DATA SOURCES: PubMed/MEDLINE/Google Scholar search (January 1, 2000-September 30, 2015) without language restriction using (tardive dyskinesia OR tardive) AND (antipsychotic*) plus specific names of SGAs. STUDY SELECTION: Of 8,895 hits, we screened 203 full-text articles for cross-sectional, rating scale-based TD rates during SGA, FGA, or FGA+SGA treatment...
January 31, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28141621/high-incidence-and-prevalence-of-drug-related-movement-disorders-in-young-patients-with-psychotic-disorders
#7
Thierry Q Mentzel, Ritsaert Lieverse, Oswald Bloemen, Wolfgang Viechtbauer, Peter N van Harten
BACKGROUND: Drug-related movement disorders (DRMDs) reduce quality of life and contribute to medication noncompliance of patients with psychotic disorders. Little is known about the epidemiology of DRMDs in relatively young patients a few years after onset of psychosis. This is an important period to study, as the impact of the antipsychotic treatment on the long-term potentiation of the neural pathways associated with psychotic disorders and DRMDs is still minimal. This study investigated the prevalence, incidence, persistence, and clinical correlates of DRMDs in patients during their first years after disease onset...
January 30, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28120489/association-study-between-the-neurexin-1-gene-and-tardive-dyskinesia
#8
Rachel Lanning, Tristram A Lett, Arun K Tiwari, Eva J Brandl, Vincenzo de Luca, Aristotle N Voineskos, Steven G Potkin, Jeffrey A Lieberman, Herbert Y Meltzer, Daniel J Müller, Gary Remington, James L Kennedy, Clement C Zai
OBJECTIVE: Tardive dyskinesia (TD) is a motor side effect that may develop after long-term antipsychotic treatment. Schizophrenia has recently been associated with the Neurexin-1 (NRXN1) gene that codes for a cell adhesion molecule in synaptic communication. METHODS: This study examined five NRXN1 single-nucleotide polymorphisms (SNPs) for possible association with the occurrence and severity of TD in 178 schizophrenia patients of European ancestry. RESULTS: We did not find these SNPs to be significantly associated with TD...
January 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28072646/clozapine-treatment-of-olanzapine-induced-tardive-dyskinesia-a-case-report
#9
Dinesh Sangroula, Inderpreet Virk, Wali Mohammad, David A Kahn
Tardive dyskinesias (TD) are serious, often irreversible side effects of dopamine blocking agents, most commonly first-generation antipsychotics. No definitive treatment exists, with different interventions showing inconsistent results. We report a case of TD presenting after 12 years of olanzapine therapy in a 66-year-old Hispanic male with paranoid schizophrenia. The TD symptoms were successfully treated within a few weeks by switching to clozapine. Two cases of olanzapine-induced TD treated with clozapine have previously been reported, but in those cases, the symptom onset was quicker, ranging from a few months to a few years after initiation of olanzapine therapy, and the treatment response was relatively slower...
January 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28067751/efficacy-of-clozapine-on-dopamine-supersensitivity-psychosis-in-schizophrenia
#10
Yusuke Nakata, Nobuhisa Kanahara, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iyo
Although the effectiveness of clozapine (CLZ) for patients with treatment-resistant schizophrenia (TRS) has been well established, its active mechanism has not been completely clarified. Several clinical studies showed that neuroleptic-induced dopamine supersensitivity psychosis (DSP) could be involved in the etiology of TRS. We preliminarily explored the possible beneficial effect of CLZ for dopamine supersensitivity schizophrenia. The present study is a case series. We followed 15 patients with DSP for about 2...
January 6, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28044943/forgotten-but-not-gone-new-developments-in-the-understanding-and-treatment-of-tardive-dyskinesia
#11
Jonathan M Meyer
The broad use of atypical antipsychotics was expected to dramatically reduce the prevalence and incidence of tardive dyskinesia (TD), but data show that TD remains an important challenge due the persistent nature of its symptoms and resistance to numerous treatment modalities, including antipsychotic discontinuation. Recent insights on genetic risk factors and new concepts surrounding pathophysiology have spurred interest in the possibility of targeted treatment for TD. As will be reviewed in this article, the number of evidence-based strategies for TD treatment is small: only clonazepam, amantadine, ginkgo biloba extract, and the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine have compelling data...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28044942/emerging-pharmacological-therapies-in-schizophrenia-what-s-new-what-s-different-what-s-next
#12
Leslie Citrome
There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28009769/movement-disorders-induced-by-the-atypical-antipsychotic-aripiprazole
#13
Karim Selfani, Valérie L Soland, Sylvain Chouinard, Philippe Huot
OBJECTIVES: Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. Because of its partial agonist activity, it was believed that aripiprazole would be less susceptible than typical antipsychotics to induce extrapyramidal side effects. However, a few case-reports and case-series detailing aripiprazole-induced movement disorders have been published, suggesting that aripiprazole-induced movement disorders may arise. Here, we seek to report further cases of aripiprazole-induced movement disorders to raise the awareness of clinicians on this adverse effect...
January 2017: Neurologist
https://www.readbyqxmd.com/read/27992257/agitation-management-in-pediatric-males-with-anti-n-methyl-d-aspartate-receptor-encephalitis
#14
Lauren T Schumacher, Andrea P Mann, James G MacKenzie
OBJECTIVES: Severe agitation is a common symptom in pediatric cases of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis-an autoimmune encephalitis with prominent neuropsychiatric symptoms. Agitation is a major barrier to treatment of the underlying disease process and increases patients' risk of harming themselves and others. Furthermore, male patients often have undetectable tumors and are especially at risk for extended hospitalization, but have been infrequently studied...
December 2016: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27978821/metabolic-syndrome-and-adverse-clinical-outcomes-in-patients-with-bipolar-disorder
#15
Ya-Mei Bai, Cheng-Ta Li, Shih-Jen Tsai, Pei-Chi Tu, Mu-Hong Chen, Tung-Ping Su
BACKGROUND: Metabolic syndrome (MetS) is highly prevalent among patients with bipolar disorder. MetS may cause complications in the brain, but studies investigating MetS-associated clinical psychiatric outcomes remain scant. METHODS: We enrolled clinically stable outpatients with bipolar disorder aged 18-65 years and performed anthropometric and fasting biochemical assessments to investigate MetS prevalence. We then performed clinical assessments by using the Young Mania Rating Scale for manic symptoms, the Montgomery-Åsberg Depression Rating Scale for depressive symptoms, the Positive and Negative Symptom Scale for psychotic symptoms, the Involuntary Movement Scale for tardive dyskinesia, the Barnes Akathisia Rating Scale for akathisia, the Udvalg for Kliniske Undersogelser for general side effects, the Schedule for Assessment of Insight for insight, the Global Assessment of Functioning scale for global functioning, and the Wisconsin Card Sorting Test (WCST) for cognitive executive function...
December 15, 2016: BMC Psychiatry
https://www.readbyqxmd.com/read/27872703/crocin-prevents-haloperidol-induced-orofacial-dyskinesia-possible-an-antioxidant-mechanism
#16
Marzyeh Kamyar, Bibi Marjan Razavi, Faezeh Vahdati Hasani, Soghra Mehri, Amir Foroutanfar, Hossein Hosseinzadeh
OBJECTIVES: Long-term treatment with antipsychotics causes serious side effects such as tardive dyskinesia that characterized by abnormal movements in the orofacial region. Oxidative stress in the brain specific area is implicated in the pathophysiology of tardive dyskinesia. In this study the protective effect of crocin on haloperidol-induced orofacial dyskinesia was evaluated. MATERIALS AND METHODS: Haloperidol (1 mg/kg, IP) and crocin (10, 20 and 40 mg/kg, IP) were administrated to rats for 21 days...
October 2016: Iranian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/27823630/ginkgo-biloba-leaf-extract-and-alpha-tocopherol-attenuate-haloperidol-induced-orofacial-dyskinesia-in-rats-possible-implication-of-antiapoptotic-mechanisms-by-preventing-bcl-2-decrease-and-bax-elevation
#17
Hui Mei An, Yun Long Tan, Jing Shi, Zhiren Wang, Meng Han Lv, Jair C Soares, Dongfeng Zhou, Fude Yang, Xiang Yang Zhang
BACKGROUND: Tardive dyskinesia (TD) is a serious side effect of long-term administration of typical neuroleptics, such as haloperidol. The pathophysiology of TD remains unclear, but the experimental evidence suggests that free radical-induced neuronal apoptosis in the basal ganglia may play an important role. PURPOSE: This study was to investigate changes in Bax and Bcl-2 expression levels in TD-associated brain regions and the effects of the antioxidant EGb761 on Bax and Bcl-2 levels in an animal model of TD...
December 1, 2016: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/27819145/dopamine-depleters-in-the-treatment-of-hyperkinetic-movement-disorders
#18
REVIEW
Joseph Jankovic
Abnormal involuntary movements often improve in response to anti-dopaminergic drugs. In contrast to classic neuroleptics that block dopamine receptors, drugs that deplete presynaptic dopamine by blocking vesicular monoamine transporter type 2 (VMAT2) seem to be safer and have little or no risk of tardive dyskinesia. This is one reason why there has been a recent emergence of novel VMAT2 inhibitors. Areas covered: Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in the treatment of chorea associated with Huntington disease (HD), other VMAT2 inhibitors (e...
December 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27818825/a-case-of-aripiprazole-induced-tardive-dyskinesia-with-dramatic-evolution
#19
Edwige Heitzmann, Hervé Javelot, Luisa Weiner, Bruno Michel
Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly...
2016: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/27816557/influence-of-magnesium-supplementation-on-movement-side-effects-related-to-typical-antipsychotic-treatment-in-rats
#20
Maikel Kronbauer, Vinicia Garzela Metz, Karine Roversi, Veronica Tironi Dias, Caren Tatiane de David Antoniazzi, Raquel Cristine da Silva Barcelos, Marilise E Burger
Chronic use of typical antipsychotic haloperidolis related to movement disturbances such as parkinsonism, akathisia and tardive dyskinesia which have been related to excitotoxicity in extrapyramidal brain areas, requiring their prevention and treatment. In the current study we evaluated the influence of the magnesium on prevention (for 28days before-), reversion (for 12days after-) and concomitant supplementation on haloperidol-induced movement disorders in rats. Sub-chronic haloperidol was related to orofacial dyskinesia (OD) and catalepsy development, increased generation of reactive species (RS) and levels of protein carbonyl (PC) in cortex, striatum and substantia nigra (SN) in all experimental protocols...
November 2, 2016: Behavioural Brain Research
keyword
keyword
39290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"